Generational bottom is in. Breakout has begunAfter forming a bullish wedge for a few months, the price went sideways for another 3 months which is a very good sign that the bottom is in.
Vaccinestocks
NVAX pushed to bottom of its channel LONGNVAX powered off its earnings and a news catalyst and is overdue now for a correction. While in
an ascending channel NVAX is now at the bottom of the channel perhaps due to the general
market moves this week. From here it can move up in the channel or breakdown and fall into
a significant correction from the uptrend since May 10th. I am bullish on NVAX and have
a prior perspective of an insider. I have realized profit six figures from my call options for
January 2025 and have a large number remaining in the trade. At this juncture, I will watch
for NVAX to move up in the channel and take a trade of shares and some call options
for 15.00 expiring in June 2025 to take advantage of long term capital gains on the options.
The FDA is currently reviewing some COVID vaccine data which is particularly relevant to
NVAX. The volume profile has a shelf at 14.25 which will be my stop loss on the shares.
The options will have a 20% stop loss. Considering the level from which NVAX has fallen over
a period of some period there is great potential in my opinion.
MRNA- a vaccine biotechnology stock LONGMRNA focuses on vaccine research and development and we are in the flu season an COVID is
lurking in the shadows and trying to make a comback. It had an excellent earnings report and
forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored
VWAP and is at the level of the first upper VWAP while in side the high volume area of the
volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing
position here and again the next time I see a dip on the 15-30-minute chart. I look forward
to take a piece out of the position after the next earnings report in about 75 days. I have an
alert for relative volume when the running mean is exceeded on the 30 minute chart which
notify me to take a look at the chart. This is illustrated on this longer time frame chart about
the days around earnings but occurs from time to time from other events. As an aside, if NVAX
gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be
the leading candidate to do a takeover, friendly or otherwise.
NVAX Novavax Vaccine approved! Buy Opportunity!If you haven`t bought NVAX during the pandemic:
Then you need to know that NVAX Novavax's recent achievements in gaining full marketing authorization for its COVID-19 vaccine, Nuvaxovid, in the UK and Singapore, alongside its availability in major U.S. pharmacies, have ignited optimism among investors. These milestones signify a bright future for NVAT stock.
The international authorization of Nuvaxovid opens doors to vast markets, enhancing revenue potential and global recognition for Novavax. the EU delayed the approval, but will update its decision by the end of this month.
Nuvaxovid's availability at CVS and Rite Aid in the U.S. immediately after regulatory clearance demonstrates its acceptance and accessibility.
Nuvaxovid is a protein-based COVID-19 vaccine, different from the mRNA vaccines of PFE and MRNA.
My price target is $10 by the end of this month.
Looking forward to read your opinion about it.
Covid & Vaccine Related Novavax Long Play in the cardsHi guys! So lately theres been some buzz on a particular variant, increased cases of hospitalizations and government backing. At risk population that require vaccinations/ boosters will always exist. Therefore, i believe this fact along with various technical analysis findings can make companies such as Biontech, Moderna and even not as famous Novavax potential plays.
(Look below for my analysis on Biontech)
Jumping right in. This is a technical analysis on Novavax (NVAX) on the 3 day timeframe.
Zoomed in we can see that we have a GOLDEN CROSS.
Between the:
21 EMA
50 SMA
Being on the 3 Day its ALOT more Powerful than having it on 1 Day and it may influence the larger timeframes. Which is what we want.
We have also maintained SUPPORT on both Moving Average. (21 EMA and 50 SMA)
This is a great sign, if we continue like how we are with our current candle during the close that would further confirm Support and a bullish case in my opinion.
This 3 day candle will close on the 8th of September. Pay attention to how big the body of candle gets on the close.
With this i would like Volume to start to pick up especially if and when we get to the "flat trendline".
Another important development to notice is the Ascending Triangle.
This can be giving us evidence we are in the process of BOTTOMING out.
Watch for the breakout ABOVE the Flatline. This with confirmation of Support on flatline would be a Major Area to take Long Positions.
I would ADVISE AGAINST buying inside the triangle. But Belowthe Ascending Support Line would be an area for Stop losses.
Watch also how the MACD acts. If we continue in Green and the Blue/Orange lines make it ABOVE 0 level. We will be off to the races, as it would be the necessary catalyst that provides momentum to have the triangle play out.
__________________________________________________________________________________
Thank you for taking the time to read my analysis. Hope it helped keep you informed. Please do support my ideas by boosting, following me and commenting. Thanks again.
Stay tuned for more updates on NVAX in the near future.
If you have any questions, do reach out. Thank you again.
DISCLAIMER: This is not financial advice, i am not a financial advisor. The thoughts expressed in the posts are my opinion and for educational purposes. Do not use my ideas for the basis of your trading strategy, make sure to work out your own strategy and when trading always spend majority of your time on risk management strategy.
BionTech Fastly Approaching Major Resistance, Will we Break?Hi Guys, this is a Technical Analysis on BionTech (BNTX) on the 3 Day Timeframe.
We are currently approaching a MAJOR RESISTANCE Trendline.
This Trend started from the TOP in 08/2021.
Everytime we've interacted with it in the past, we've been REJECTED.
Will we get Rejected again?
Well, we've had 3 touch points already. In trendline theory, it states that atleast 3 touches are required before a trendline is weak enough to break through. So, it is possible that a break can occur.
With risk of new variants, hospitalizations of COVID increasing and a push of government to get people to get boosters, this could be a chance for Trend change to UPSIDE for BNTX.
BUT just looking at it in a pure TA lens, i wouldn't just start buying now.
I would wait for a break above the Trendline and CONFIRMATION above it.
Also with the break, note that VOLUME should be spiking and increasing.
We should not see a DECLINE in Volume as we break through.
That can be signs of a FAKEOUT.
We are also reaching some Resistance from a Support line turned Resistance line.
Now lets look at our indicators for more evidence.
RSI -> We've had the Lowest RSI reading on May 09,2023 EVER in BNTX history. This could be a catalyst for more buying pressure and a trend change. We also broke above RSI Red Resistance line.
MACD-> A momentum indicator, has crossed BULLISH, below the 0 level. If we continue this bullish momentum and the Blue/Orange lines move above the 0 level, this can be inject the well needed momentum for BNTX to increase in price.
STOCH RSI -> Is also in a BUllish cross and it shows that theres plenty of room for momentum to continue.
__________________________________________________________________________________
Thank you for taking the time to read my analysis. Hope it helped keep you informed. Please do support my ideas by boosting, following me and commenting. Thanks again.
Stay tuned for more updates on BNTX in the near future.
If you have any questions, do reach out. Thank you again.
DISCLAIMER: This is not financial advice, i am not a financial advisor. The thoughts expressed in the posts are my opinion and for educational purposes. Do not use my ideas for the basis of your trading strategy, make sure to work out your own strategy and when trading always spend majority of your time on risk management strategy.
Target 80Following weekly chart.
- Now covid variant on the way
- Novavax vaccine is working for the new variant, if it spreads more, company is on a way to make good money.
And technically we're on a deep.
TP1 - Following EMA100 for a first target
TP2 - 80 is a nice area as a fibonacci level and a resistance.
TP3 - Planinng to hold some till 250, it reached 2 times before, why not a 3rd time?
SL is clear, stop when there is a new low.
BNTX biotech / currency play LONGBNTX a Germany company in the biotechnology and vaccine sectors out of Europe
and Germany is looking good on the 2H chart here with a volume profile and an
intermediate term VWAP overlaid. Price bounced off the bottom of the high volume
area of the volume profile and looks to be ready for a reversion to the mean and even
a sling-short move. The target here is the double top M pattern of mid July at 114.
The VPT and MACD are confirmatory of a momentum flip making for a long trade
entry. I will review the options chain for a suitable options trade with a narrow bid/ask
spread, suitable volume and open interest. If I cannot find one I'll take a trade of
10-20 shares of stock with a stop-loss of 105 to back up this trade while NVAX and MRNA
are also making moves.
MRNA a medical Technology Stock LONG MRNA is a medical technology company. It is in the vaccine sector and competes ( well) with
NVAX and PFE among others. Earnings are upcoming on 8/3 in about a week.
On the 30 minute chart it appears to be in a descending wedge pattern which is typically
a bottoming with a breakout over and beyond the descending trendline. The relative
trend indicator shows the downtrend to be a slow grinding type trend with some minor
corrections along the way. As might be expected the RS lines are low in the indicator's
channel. I see this as a setup for a pre-earnings play with the expectation that MRNA
could breakout above the resistance trend line and move toward the horizontal resistance
of the triple top earlier in mid-July. I see medical stocks as a good alternative to technology
stocks that may be overextended and stressed by the current financial chaos pressuring
the markets. Another approach is a two call options targeting $ 125 expiring 8/11
and running the first until 100% profit or 8/2, the day before the expiration whichever
comes first and letting the other run through earnings into the middle of the following
week at 8/9. I always like to cut these short of expiration by a few days to diminish the
effects of time decay.
Can VBIV jump again like earlier this month?VBIV popped 50 % to begin July and then promptly lost 75% and has been low volume and
sideways since. I have not been able to discern any catalyst for that action. Earnings show
an ongoing cash burn. In the past couple of days, the Price Volume Trend indicator has
detected a small increase in the price volume product. The Relative Trend Index (RTI) indicator
has gone from negative to positive on July 18th while the dual time frame RSI indicator
showing 1 hour TF in blue and daily TF in black has shown bullish divergence with the lines
rising over the 50 level and the blue line above the black line. Price crossed a VWAP band line
on July 18th as well. The analysis supports a bullish bias and a set up for a long trade.
I will trade long and find an entry on a 15 - 30 minute chart looking for a pivot low
to take that position. I will target 2.25 and 3.00 for the time being.
Will Novavax NVAX go higher? SHORTNVAX popped today for a price jump of more than 20%. Canada agreed to pay out on a contract
for COVID vaccines it now does not want in the amount of $350M. This is hardly enough to
the fundamentals of the company overall. So the question arises, have traders and / or
investors overreacted to a one time bonus which is essentially revenue without overhead and
expense. My opinion is that this is an overreaction and that the price will drop after the
pop hits a high. Buying long right now is essentially the risk of buying a high that will not
go higher. On the Chris Moody dual RSI indicator, the longer one hour TM in black is over
75 while the shorter 5 minute TM in blue has peaked and dropped from 95 to 60. This is
in essence bearish divergence. The other indicator, the mass index, shows the value
arriving at the reversal zone where a drop to below 26.5 will be the trigger.
Overall, for both fundamental and technical reasons, I will enter a short trade on NVAX
expecting a correction / pullback from the pop the stock got after a one-time bonus of
a payout for not producing unneeded vaccines.
Can NVAX rise again?NVAX has had significant down trending over a wide range of time. On the 4H chart it seems to
be pivoting from a swing bottom 3-4 days ago. This is accompanied by a cross of the MACD
lines under the histogram on that indicator and a flip of volatility on the relative volatility
indicator. NVAX has been subject to significant short selling. Price is presently nearly
two standard deviations below the mean anchored VWAP set in mid May. Basically it is in
deep undervalued oversold territory and now with a rise. The volume profile has a point of
control level considerably above the mean VWAP. This is the level with the highest volume
of trades showing most trades occurred well above VWAP. This would be traders taking
profit and selling or alternatively short sellers opening a position but more likely a combination
of them. Price wants to ascend to at least VWAP if not the POC line. My analysis is that
any significant rise could begin a squeeze on short positions. Those closing with a buy to
cover trade would in effect be synergizing new buyers and add to the bullish momentum,
Accordingly, I will open a position early and see if I can get in ahead of a potential
short squeeze. While speculative, a narrow stop loss at 6.80 the second band line below
the mean VWAP will take a lot of risk off the trade and allow me to be patient comfortably
watching the price action.
EBS a biotech company focused on vaccinesEBS is a small biotechnology company whose forte is the clean processing and manufacturing
facility that the FDA requires for certain bioprocessing to be certified for delivery of products
to end-user patients. It is not a research facility like the one in China that accidentally released
COVID and the global impact will be likely felt for another decade. EBS does depend on
federal support and income from contract work from vaccine manufacturers. There is
reasonable expectation or persistent and consistent revenues ongoing without fail unless
the FDA decertified the facilities. On the chart, EBS is in a flat bottom triangle on its base.
It is presently rising out of the triangle and towards the mean anchored VWAP It is just above
The POC line which functions as dynamic support in the demand zone. I see a long trade
with the stop loss below the POC line, the first target the blue line representing one standard
deviation above the mean VWAP at about 9.4 while the second target is the redline two
standard deviations above the mean VWAP at about 10.05 while the final target contemplates
that EBS will challenge the high in May of 10.75.
MRNA ? Buy Weakness MRNA descended this past winter off a head-and-shoulders pattern on the daily chart just under
the demand zone as shown by the LuxAlgo indicator. Price is now in a downtrend heading into
earnings tomorrow. MRNA needs to show something good otherwise it will break through the
demand zone and keep going down.
This is a risky earnings play betting that something will show up on the report to buoy up the
company and its stock. I will risk 0.01% of the trading account on a call option with DTE 5/19/23
looking for a minor surge and so a good quick profit.
( see also the link below)
VAXX Biotech Penny Stock Earnings Play VAXX is a speculative penny biotechnology NASDAQ stock with high volatility. On the 2H chart, it is currently trending up from a swing low
on April 25 with earnings to be reported Monday 5/8. May's relative volume compared with that of April is about 2-3X higher. To confirm
the bullish bias, VAXX is currently trading above its intermediate-term POC line on the volume profile. This confirms buyers as being in
control. Although this is speculative as are all biotechnology penny stocks, impending earnings as a catalyst has been considered.
Continued development in the vaccine subsector at large may suggest VAXX may have a favorable report to fuel further price action.
BNTX: NICE BOTTOMING BASE ON THIS VACCINE PLAYBNTX (BioNTech) Healthcare sector
German company. Produce the BioNTech biotechnology. Partnership with Pfizer.
Nice long bottoming base since March.
Triple bottom .
It looks like a rectangle pattern .
All moving averages turning up .
A move above the blue zone (>195) could take it to 248 and maybe more.
I'm long with a stop at 165.
Trade safe!
Moderna Progress on all VaccinesThe statistics are between $184 - $219(1 Year)
Its Financial Health is very strong.
Why not wait till Moderna makes greater progress and finds It
Resistance Again at $450
Moderna has many projects running.
So if we see progress in some of the projects in the next Years,
we will see a great price rise.
I believe it won't be difficult to reach its older resistance again, around $450.
Disclaimer:
Just my Idea! Find your Trading Ideas and learn and study more!
Moderna in trouble? Moderna
Short Term - We look to Sell at 149.49 (stop at 160.31)
Preferred trade is to sell into rallies. Closed below the 20-day EMA. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. We look to set shorts in the early trade.
Our profit targets will be 123.84 and 103.50
Resistance: 150.00 / 171.76 / 187.50
Support: 125.00 / 120.00 / 104.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
Will the Moderna share price ever recover?The Moderna share price has fallen from its pandemic peak amid uncertain demand for its lifesaving mRNA vaccine. But will it ever recover?
Moderna (NASDAQ:MRNA) shares traded for more than $450 last summer. But today the stock is trading at $136 – less than a third of its pandemic peak. The vaccine-maker stock gained massively during the pandemic. Its mRNA vaccine was favoured by governments around the world, including in the US and EU. In fact, its shot was famously touted as the Rolls-Royce of vaccines, although it was also linked with very rare cases of myocarditis that perhaps caused it to be less popular than the Pfizer vaccine by those being vaccinated. Prior to the pandemic, the Massachusetts-based firm was trading for less than $15 a share.
But what comes next for Moderna? Will it return to its 2021-highs, or will it continue to fall?
Why is the share price falling?
Moderna only has one commercial product and that’s its lifesaving Covid-19 vaccine, Spikevax. The shot received emergency approval around the world in 2020 and 2021 and is considered one of the most effective vaccines in the fight against Covid-19. Like other vaccines, Spikevax was developed and approved on an accelerated schedule. While it is normal for vaccine development to take a decade from discovery to rollout, Spikevax was created and rolled out within a year.
These exceptional circumstances propelled Moderna from a company that most people had never heard of, to a household name worldwide. Its shot was one of the first four vaccines approved for use against the virus in the West. The other vaccines included the AstraZeneca shot that was sold for cost-price by the Anglo-Swedish drugs company. However, the Moderna vaccine was sold, and continues to be, for around $20-25 a dose.
In turn, this saw Moderna generate $18,4bn in 2021. The figure represents an enormous 2191% jump from 2020. In 2020, the vaccine maker saw revenues of $803m. This figure also represented a huge 1234% increase from the $60m generated in 2019. As such, we can see how the pandemic generated revenue growth in a way which is not likely to be repeated.
Moderna has strong forecasts for 2022, but the future is uncertain after that. The firm, which currently has a market cap of $55bn, says it is on track to deliver $21bn in revenue in 2022. However, forecasts from then on are mixed. While the general forecast is steeply downwards. Some analysts have predicted that Moderna’s vaccine sales will dip as low as $2bn in 2024.
So, investors are clearly concerned about revenue generation in years to come. And I think as we look around us, we can see that demand for Covid-19 vaccines is dropping. Not only among governments, but among normal citizens. Only elderly members of the British public are being offered fourth jabs right now and I’m not sure whether younger members of the population will be given free Covid-19 shots again.
What could send the share price upwards?
The less virulent nature of the Omicron strain has made vaccinations less vital. While Omicron is considerably more contagious than previous variants, it causes less severe symptoms. One thing that would send the Moderna share price soaring is the emergence of a more virulent strain, which would incentivise more vaccination. However, viruses don’t tend to evolve to become more deadly. The most successful viruses are the ones that spread, not the ones that kill their hosts.
The second thing that could reverse the negative trend in the share price is the development or launch of new products with commercial potential. mRNA technology has been lauded as having the capacity to be more easily manufactured to take on diseases such as cancer. However, the majority of Moderna’s vaccines in development concern Covid-19 and other respiratory viruses.
Moderna has two combined respiratory-virus vaccine candidates in its pipeline. One targets influenza and Covid-19. The other targets flu, Covid-19, and respiratory syncytial virus (RSV). Both candidates are in preclinical development. This sort of product could enhance the firm’s revenue generation capability, but it seems unlikely that such vaccines would be rolled out to whole populations. Instead, it would be targeted at the most vulnerable, probably just in time for the winter months. However, competitor Novavax is slightly closer to commercialising a similar product.
Moderna also has a Cytomegalovirus (CMV) vaccine in phase three trials. CMV is related to the herpes virus that causes cold sores and chickenpox. However, once you have the virus, you retain it for life. It can cause serious health problems in some babies who get the virus before birth and in adults with weakened immune systems.
The biotech firm is also developing a Zika vaccine and a personalized cancer vaccine (PCV). The PCV is in phase two trials and such vaccines, if successful, are likely to be very lucrative. The disease is one of the biggest killers worldwide and treatment can be very costly. Moderna is also working on a HIV vaccine. However, many of Moderna’s vaccines are still some distance from commercialisation. Reaching commercialisation can take a decade or longer.
Valuation
Because of the uncertain future, Moderna looks very cheap by some metrics. The biotech firm has a price-to-earnings (P/E) ratio of just four, based on its profits over the past 12 months. It also has a price-to-sales ratio of just 2.4. Moderna’s valuation is quite unique in many respects. Growth stocks tend to be expensive as they’re partially valued on future revenue potential rather than their current earnings. However, Moderna growth appears to have been short-lived, and it seems unlikely that such revenue growth can be repeated in the future.
With peak demand for Covid-19 vaccines likely past, an increase in the share price, at least in the short term, seems unlikely. However, I don’t see the stock’s share price falling much further. One forecast suggests that Moderna’s profits could fall to $2bn in 2024. If the market cap remained the same as it is today, $2bn in profit would give Moderna a P/E ratio of around 27 in 2024. That’s still expensive by some metrics, but biotech firms tend to trade at a premium given their valuation reflects future earnings potential. And Moderna clearly has some potential beyond its current Covid jab.
NVAX room to the downsideDescending triangle break on the daily and now forming a bear flag for a possible leg lower.
Watching the flag break and confirmation.
Another confirmation could be 56.85 price level.
Targets: $50 , 47.93
GOVX Corporate Update soon | 10X Upside Potential Analyst RatingGOVX GeoVax Labs is a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer.
GeoVax Labs will report Q1 2022 financial results on April 27.
Jason McCarthy from Maxim Group has a $10.00 price target for GOVX.
The stock is now $1.01.
Market Cap of only 7.23Mil.
This is a 4X upside potential short term stock in my opinion.
Chaos Reigns Hah... These trend lines are the accumulation of attempts to figure this thing out over the last year. Ridiculous price action but learned to leverage the volatility and play the extremes.
Currently at a relative downside extreme. Also signs of Wyckoff Accumulation similar to the build up when it popped Jan 2021.
Time series 1-month point forecast target is 163, NVAX price action is cyclical so these forecasts are more difficult than when there is merely trend/seasonality.
Technical levels I’m looking for to the upside are 111-120, 146, 180. Catalysts are here so it’s now or never I guess and calls are relatively cheap.
Not financial advice.
Novavax Breaking Out? Novavax - Short Term - We look to Buy at 83.80 (stop at 75.92)
Price action has posted a bullish Engulfing Candle and is positive for short-term sentiment. We look for gains to be extended today. Short term oscillators have turned positive. Although the bears are in control, the stalling negative momentum indicates a turnaround is possible.
Our profit targets will be 101.48 and 112.00
Resistance: 90.00 / 100.00 / 140.00
Support: 70.00 / 60.00 / 50.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
